Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Alas S and Bonavida B (2001) Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 61: 5137–5144
Alas S, Emmanouilides C and Bonavida B (2001) Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 7: 709–723
Bubien JK, Zhou LJ, Bell PD, Frizzell RA and Tedder TF (1993) Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol 121: 1121–1132
Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K, Pearson M, Waselenko JK, Ling G, Grever MR, Grillo–Lopez AJ, Rosenberg J, Kunkel L and Flinn IW (2001) Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19: 2153–2164
Casey PJ (1995) Protein lipidation in cell signaling. Science 268: 221–225
Clynes R, Takechi Y, Moroi Y, Houghton A and Ravetch JV (1998) Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci USA 95: 652–656
Clynes RA, Towers TL, Presta LG and Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6: 443–446
Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson PW, Lister TA, Feuring-Buske M, Radford JA, Capdeville R, Diehl V and Reyes F (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92: 1927–1932
Coiffier B, Lepage E, Herbrecht R, Tilly H, Solal-Celigny P, Munck JN, Bouabdallah R, Lederlin P, Sebban C, Morel P, Haioun C, Salles G, Molina T and Gisselbrecht C (2000) Mabthera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): interim results of a randomized GELA trial. Blood 96: 223a
Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, Deconinck E, Haioun C, Foussard C, Sebban C, Stamatoullas A, Milpied N, Boue F, Taillan B, Lederlin P, Najman A, Thieblemont C, Montestruc F, Mathieu-Boue A, Benzohra A and Solal-Celigny P (2001) Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97: 101–106
Cragg MS, French RR and Glennie MJ (1999) Signaling antibodies in cancer therapy. Current Opinion Immunol 11: 541–547
Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio A, Jonas C, Klipperstein D, Dallaire Bk and Varns C (1999) Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. Journal of Clinical Oncology 17: 268–276
Czuczman MS, Grillo-Lopez AJ, McLaughlin P, White CA, Saleh M, Gordon L, LoBuglio AF, Rosenberg J, Alkuzweny B and Maloney D (2001) Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Ann Oncol 12: 109–114
Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J and Levy R (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of retreatment. J Clin Oncol 18: 3135–3143
Deans JP, Kalt L, Ledbetter JA, Schieven GL, Bolen JB and Johnson P (1995) Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20. J Biol Chem 270: 22632–22638
Deans JP, Robbins SM, Polyak MJ and Savage JA (1998) Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment. J Biol Chem 273: 344–348
Einfeld DA, Brown JP, Valentine MA, Clark EA and Ledbetter JA (1988) Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. Embo J 7: 711–717
Foran JM, Cunningham D, Coiffier B, Solal-Celigny P, Reyes F, Ghielmini M, Johnson PW, Gisselbrecht C, Bradburn M, Matthews J and Lister TA (2000a) Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol 11: 117–121
Foran JM, Gupta RK, Cunningham D, Popescu RA, Goldstone AH, Sweetenham JW, Pettengell R, Johnson PW, Bessell E, Hancock B, Summers K, Hughes J, Rohatiner AZ and Lister TA (2000b) A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol 109: 81–88
Foran JM, Rohatiner AZ, Cunningham D, Popescu RA, Solal-Celigny P, Ghielmini M, Coiffier B, Johnson PW, Gisselbrecht C, Reyes F, Radford JA, Bessell EM, Souleau B, Benzohra A and Lister TA (2000c) European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. Journal of Clinical Oncology 18: 317–324
Ghetie MA, Bright H and Vitetta ES (2001) Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 97: 1392–1398
Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, Tedesco F, Rambaldi A and Introna M (2000) Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95: 3900–3908
Golay JT, Clark EA and Beverley PC (1985) The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J Immunol 135: 3795–3801
Hainsworth JD, Burris HA 3rd, Morrissey LH, Litchy S, Scullin DC Jr., Bearden JD 3rd, Richards P and Greco FA (2000) Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 95: 3052–3056
Harjunpaa A, Junnikkala S and Meri S (2000) Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 51: 634–641
Hoffman M and Auerbach L (2000) Bone marrow remission of hairy cell leukaemia induced by rituximab (anti-CD20 monoclonal antibody) in a patient refractory to cladribine. Br J Haematol 109: 900–901
Johnson PWM, Swinbank K, MacLennan S, Colomer D, Debuire B, Diss T, Gabert J, Gupta RK, Haynes A, Kneba M, Lee MS, Macintyre E, Mensink E, Moos M, Morgan GJ, Neri A, Johnson A, Reato G, Salles G, van’t Veer MB, Zehnder JL, Zucca E, Selby PJ and Cotter FE (1999) Variability of polymerase chain reaction detection of the Bcl2-IgH translocation in an International multicentre study. Ann Oncol 10: 1349–1354
Kansas GS and Tedder TF (1991) Transmembrane signals generated through MHC class II, CD19, CD20, CD39, and CD40 antigens induce LFA-1-dependent and independent adhesion in human B cells through a tyrosine kinase-dependent pathway. J Immunol 147: 4094–4102
Kanzaki M, Shibata H, Mogami H and Kojima I (1995) Expression of calcium-permeable cation channel CD20 accelerates progression through the G1 phase in Balb/c 3T3 cells. J Biol Chem 270: 13099–13104
Kuehnle I, Huls MH, Liu Z, Semmelmann M, Krance RA, Brenner MK, Rooney CM and Heslop HE (2000) CD20 monoclonal antibody (rituximab) for therapy of Epstein–Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 95: 1502–1505
Magni M, Di Nicola M, Devizzi L, Matteucci P, Lombardi F, Gandola L, Ravagnani F, Giardini R, Dastoli G, Tarella C, Pileri A, Bonadonna G and Gianni AM (2000) Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 96: 864–869
Mathas S, Rickers A, Bommert K, Dorken B and Mapara MY (2000) Anti-CD20-and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res 60: 7170–7176
McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D and Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology 16: 2825–2833
Milpied N, Vasseur B, Parquet N, Garnier JL, Antoine C, Quartier P, Carret AS, Bouscary D, Faye A, Bourbigot B, Reguerre Y, Stoppa AM, Bourquard P, Hurault de Ligny B, Dubief F, Mathieu-Boue A and Leblond V (2000) Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 11: 113–116
O’Brien SM, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J, Lerner S and Keating MJ (2001) Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19: 2165–2170
O’Keefe TL, Williams GT, Davies SL and Neuberger MS (1998) Mice carrying a CD20 gene disruption. Immunogenetics 48: 125–132
Polyak MJ, Tailor SH and Deans JP (1998) Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment. J Immunol 161: 3242–3248
Press OW, Appelbaum F, Ledbetter JA, Martin PJ, Zarling J, Kidd P and Thomas ED (1987) Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 69: 584–591
Saleh MN, Gutheil J, Moore M, Bunch PW, Butler J, Kunkel L, Grillo-Lopez AJ and LoBuglio AF (2000) A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 27: 99–103
Shan D, Ledbetter JA and Press OW (1998) Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91: 1644–1652
Smeland E, Godal T, Ruud E, Beiske K, Funderud S, Clark EA, Pfeifer-Ohlsson S and Ohlsson R (1985) The specific induction of myc protooncogene expression in normal human B cells is not a sufficient event for acquisition of competence to proliferate. Proc Natl Acad Sci USA 82: 6255–6259
Stashenko P, Nadler LM, Hardy R and Schlossman SF (1980) Characterization of a human B lymphocyte-specific antigen. J Immunol 125: 1678–1685
Szollosi J, Horejsi V, Bene L, Angelisova P and Damjanovich S (1996) Supramolecular complexes of MHC class I, MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY. J Immunol 157: 2939–2946
Tedder TF and Schlossman SF (1988) Phosphorylation of the B1 (CD20) molecule by normal and malignant human B lymphocytes. J Biol Chem 263: 10009–10015
Tedder TF and Engel P (1994) CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 15: 450–454
Vitetta ES and Uhr JW (1994) Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy. Cancer Res 54: 5301–5309
Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, Lowe A, Kunkel LA and Fisher RI (2001) Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 19: 389–397
Voso MT, Pantel G, Weis M, Schmidt P, Martin S, Moos M, Ho AD, Haas R and Hohaus S (2000) In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol 109: 729–735
Witzig TE, White CA, Gordon li, Murray JI, Wiseman GA, Emmanouilides C, Czuczman MS, Shen D, Multani P and Grillo-López AJ (2000) Final results of a randomized controlled study of the Zevalin™ radioimmunotherapy regimen versus a standard course of rituximab immunotherapy for B-cell NHL. Blood,
Zinzani PL, Ascani S, Piccaluga PP, Bendandi M, Pileri S and Tura S (2000) Efficacy of rituximab in hairy cell leukemia treatment. J Clin Oncol 18: 3875–3877
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Johnson, P., Glennie, M. Rituximab: mechanisms and applications. Br J Cancer 85, 1619–1623 (2001). https://doi.org/10.1054/bjoc.2001.2127
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.2127
This article is cited by
-
Fundamental concepts of protein therapeutics and spacing in oncology: an updated comprehensive review
Medical Oncology (2023)
-
Anti-rituximab antibodies in pediatric steroid-dependent nephrotic syndrome
Pediatric Nephrology (2022)
-
Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab
Pediatric Nephrology (2017)
-
Biological Therapies for Rheumatoid Arthritis: Progress to Date
BioDrugs (2013)
-
Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature
International Urology and Nephrology (2013)